Abstract #1790

Kumar V, Jagannathan N, Kumar R, Jindal L, Thulkar S, Gupta S, Dwivedi S, Hemal A, Gupta N, Nayyar R

Cancer can be detected in only 30% men with serum prostate specific antigen < 10 ng/mL. There are no markers to identify patients who are unlikely to have cancer and can thus avoid a biopsy. Magnetic resonance spectroscopic imaging (MRSI) identifies areas of abnormal metabolism that may harbor cancer. We prospectively evaluated the use of MRSI to identify patients who are unlikely to have a cancer detected on their biopsy. None of the patient who had no evidence of malignancy in MRSI was found to have cancer on the sextant TRUS guided biopsy. These patients may not harbor clinically relevant cancer prostate and MRSI may have potential to avoid biopsy.